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Objectives:  Repetitive  transcranial  magnetic  stimulation  (rTMS)  is  a potential  therapeutic  intervention  for
the treatment  of addiction.  This  critical  review  aims  to  summarise  the  recent  developments  with  respect
to the  efﬁcacy  of rTMS  for all types  of addiction  and  related  disorders  (including  eating  disorders),  and
concentrates  on  the associated  methodological  and technical  issues.
Methods:  The  bibliographic  search  consisted  of a computerised  screening  of the  Medline  and  ScienceDirect
databases  up  to December  2013.  Criteria  for inclusion  were  the  target  problem  was  an  addiction,  a  related
disorder,  or  craving;  the intervention  was  performed  using  rTMS;  and the study  was  a  clinical  trial.TMS
ranscranial magnetic stimulation
ddiction
ubstance use disorder
ehavioural addiction
Results:  Of  the  potential  638  articles,  18  met  the  criteria  for inclusion.  Most  of  these  (11 of the  18)  sup-
ported  the  efﬁcacy  of  rTMS,  especially  in the short  term.  In  most  cases,  the main  assessment  criterion
was  the  measurement  of  craving  using  a Visual  Analogue  Scale.
Discussion:  The  results  are  discussed  with  respect  to the  study  limitations  and,  in particular,  the  many
methodological  and  technical  discrepancies  that  were  identiﬁed.  Key  recommendations  are  provided.ating disorder
raving
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. Introduction
Addictions are complex illnesses, and are the subject of many
esearch studies. A recent review paper suggested that over half
he adult population of the United States reported symptoms
eminiscent of current addictive disorders (Sussman et al., 2011).
ddictions can be deﬁned as “a condition in which a behaviour
hat can function both to produce pleasure and to reduce painful
ffects is employed in a pattern that is characterised by two key
eatures: (1) recurrent failure to control the behaviour, and (2)
ontinuation of the behaviour despite signiﬁcant harmful con-
equences” (Goodman, 1990, 2008). Despite this minimalist but
enerally agreed upon behavioural deﬁnition, different addictions
isplay many similarities in terms of risk factors, the frequency of
omorbidities and the trajectory, which is marked by periods of
elative control or abstinence alternating with periods of relapse
Goodman, 2008). Finally, different types of addiction share a
umber of clinical symptoms such as drug-seeking behaviour,
eelings or thoughts directed towards pathological behaviour per-
ading the mind and impulsive action followed by periods of
truggle with anxiety of varying length (Le Moal and Koob, 2007;
ickson et al., 2011). Compulsivity and impulsivity are the two
ain factors involved in a composite addiction cycle, which can
e characterised by three successive stages: binge/intoxication,
ithdrawal/negative affect, and preoccupation/anticipation, also
nown as the “craving stage” (Koob and Volkow, 2010).
Addictions are not only limited to substance use disorders (SUD).
ndeed, it is now widely agreed that they also relate to non-drug
ehaviours (e.g. gambling or shopping) and substances that have
ot traditionally been viewed as addictive (e.g. food) (Gearhardt
t al., 2011). Whether they are linked to SUD or behavioural addic-
ions, also known as “related disorders” (RD), they actually have a
reat deal in common despite their apparent clinical heterogene-
ty and mainstream thinking increasingly views SUD and RD as a
oherent whole. This is highlighted in the latest version of the Diag-
ostic and Statistical Manual of Mental Disorders (DSM-5), where
 new category entitled “Addiction and RD” combines SUD and
ambling disorders and drops the former categories of abuse and
ependence (O’Brien, 2011). Although not included in the DSM-
, several other disorders were considered relating to the Internet,
ex, exercise and shopping (Potenza, 2014a). It is expected that this
ist is non-exhaustive. Addiction relating to food was  not consid-
red by the research workgroup, due to existing debates on the
opic (Potenza, 2014a), and grouping eating disorders under the
abel “addictions” remains controversial. Despite this, more and .  . .  . . .  . . . .  .  . .  . . .  . . . . . . .  .  . . . .  .  . . .  . . . .  . . .  . . . .  . . . .  . .  . . . .  .  . . . .  . .  . .  .  .  . . . . .  . . . . 610
more authors support this idea (Speranza et al., 2012; Potenza,
2014b). The umbrella term of eating disorders encompasses a broad
spectrum, with anorexia nervosa (AN) at one end and binge eat-
ing disorder (BED) at the other, and also includes bulimia nervosa
(BN) and other speciﬁed feeding and eating disorder (OSFED). BN,
BED and, to a lesser extent, OSFED share behavioural and clini-
cal characteristics with other types of addictive disorders (Volkow
and O’Brien, 2007; Kinzl and Biebl, 2010; Gearhardt et al., 2011;
Speranza et al., 2012; Davis, 2013; Curtis and Davis, 2014). In par-
ticular, they meet the diagnostic criteria proposed by Goodman
(Goodman, 2008; Speranza et al., 2012). They also share neurobio-
logical processes with other addictive disorders (Cota et al., 2006;
Cowin et al., 2011; Gearhardt et al., 2011; Avena and Bocarsly, 2012;
Umberg et al., 2012; Kaye et al., 2013; Volkow et al., 2013). Con-
ceptualising AN as a behavioural addiction is perhaps somewhat
more complicated. Indeed, people with AN are not addicted to food
but quite the opposite, they are addicted to food deprivation, and
they show real determination instead of losing control. Because of
these opposing behavioural features, AN and BN could be regarded
as two  sides of the same coin. In particular, they are characterised
by a persistent preoccupation with food and dysfunctional cogni-
tion related to body weight and body image (Avena and Bocarsly,
2012), and by the same brain alterations, for example, increased
grey matter volume of the medial orbitofrontal cortex and reduced
white matter in the right temporal and parietal areas relative
to healthy individuals (Frank et al., 2013). The neural molecular
events driving self-restriction are detected in the nucleus accum-
bens, strengthening the idea of the addictive facet of restrictive diet
underpinned by a rewarding effect associated with energy expen-
diture (Jean et al., 2012). For all of these reasons, AN could also
be considered as a behavioural addiction or a RD, especially of the
binge-eating/purging type.
Craving is one of the most striking symptoms of addiction and
RD, as emphasised by the composite addiction cycle previously
mentioned (Koob and Volkow, 2010). It has been the subject of
growing attention, to the extent that it is listed as one of the diag-
nostic criteria in the category “Addiction and RD” (O’Brien, 2011).
Craving is deﬁned as a pressing, urgent and irrepressible desire to
give in to an addictive behaviour, and results in the loss of con-
trol in most cases (Skinner and Aubin, 2010). In addition to the
extensive literature in the ﬁeld of drug craving, there is also a wide
range of information about food craving (Bou Khalil and El Hachem,
2013; Jansen et al., 2013). Beyond the mere desire to take a drug or
food or to gamble, for example, craving also includes the expecta-
tion of positive effects and the relief of negative effects as a result
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f this action (Young and Wohl, 2009). It is a persistent symp-
om that can arise spontaneously or be cue-induced by exposing
he subject to various stimuli related to the addictive behaviour
hrough classical conditioning (Watson, 1913). Incidentally,
nimal models of craving are based on two behaviours: drug-
eeking induced by drugs or stimuli previously associated with
rug-taking, and drug-seeking induced by an acute stressor or a
esidual negative emotional state (Koob and Volkow, 2010). It is
ossible to generalise this phenomenon to food craving (Avena and
ocarsly, 2012; Marco et al., 2012). Despite long periods of absti-
ence, craving can reappear and increase the likelihood of relapse
Koob and Volkow, 2010; Skinner and Aubin, 2010; Marhe et al.,
013). Special attention must therefore be paid to managing crav-
ngs during the treatment of an addicted subject. Craving can also
e cue-induced in an experimental setting to gain a better under-
tanding of the role it plays in the decision-making process and
o determine its neuro-cognitive correlates, as well as to test the
fﬁcacy of medication in reducing craving scores (Franklin et al.,
011; Potenza et al., 2012; Goldman et al., 2013; McGrath et al.,
013; Veilleux et al., 2013). Studies have shown that cravings are
nderpinned by activation of the reward and motivation circuits
McBride et al., 2006; Wang et al., 2007; Wing et al., 2012; Goldman
t al., 2013; Jansen et al., 2013; Volkow et al., 2013). According
o these authors, the main neural structures involved are: the
ucleus accumbens, dorsal striatum, orbitofrontal cortex, anterior
ingulate cortex, dorsolateral prefrontal cortex (DLPFC), amygdala,
ippocampus and insula. While the left DLPFC, as determined by
MRI, appears to play a crucial role in increasing self-control over
ravings (Hayashi et al., 2013), the right DLPFC may  be involved
n the inhibitory control of affective impulses (Pripﬂ et al., 2013a).
owever, a lack of empirical evidence for hemispheric differences
n DLPFC in addiction excludes deﬁnitive conclusions.
Aside from the many features these disorders share, as men-
ioned above, there are also similarities in the therapeutic
pproaches (Goodman, 2008). These are most often based on
sychotherapy, which is administered using a range of different
ethods (Goodman, 1990; Potenza et al., 2011). For more than
0 years, researchers have been developing methods for adju-
ant care, particularly in the ﬁeld of pharmacotherapy (Potenza
t al., 2011). Many different molecules have been tested. Unfortu-
ately, the results of such trials have not been completely successful
n meeting expectations (Achab and Khazaal, 2011; Muller et al.,
011; Bolt et al., 2012; Mariani and Levin, 2012). More recently,
ew treatment modalities such as brain stimulation have been
xplored.
Transcranial magnetic stimulation (TMS) is a medical tool that
rst appeared over 20 years ago (Barker, 1999). This neuromod-
lation technique is based on the principle of electromagnetic
nduction and consists of magnetic pulses to induce electrical
urrents in the brain via a coil placed on the scalp. This leads
o cerebral neuromodulation through the modiﬁcation of corti-
al excitability (Daskalakis et al., 2006), of blood ﬂow to the area
Bestmann et al., 2005), of the frequency of neuronal discharge
Barr et al., 2009), and of the release of neurotransmitters such as
opamine (Strafella et al., 2003; Cho and Strafella, 2009). In addi-
ion to its cortical action, TMS  is said to act remotely on deeper
tructures, via brain circuits and interhemispheric connections (Fox
t al., 1997). Initially, TMS  was used to study motor conductivity;
owever, the effect of stimulation was extremely short-lived and
isappeared almost instantaneously. Later, the ability to deliver
ultiple pulses via repetitive TMS  (rTMS) enabled longer lasting
ffects and investigations into cognition, brain-behaviour relations
nd the pathophysiology of various neurologic and psychiatric
isorders (Wassermann and Lisanby, 2001; Kobayashi and Pascual-
eone, 2003; Tassinari et al., 2003; Rossi and Rossini, 2004; Ridding
nd Rothwell, 2007). High frequency (HF) stimulation (>5 Hz) Biobehavioral Reviews 47 (2014) 592–613
is considered to have excitatory effects on the cortical activity
whereas low frequency (LF) stimulation (<1 Hz) is considered to
have inhibitory effects (Pascual-Leone et al., 1994). Animal and
human studies have concluded that rTMS may  have a therapeu-
tic effect by altering cortical excitability through the modulation
of neurotransmitters including dopamine and GABA (Barr et al.,
2011). Successive studies have broadened the range of therapeutic
applications in the ﬁeld of neurological, re-educational and psychi-
atric pathologies. One line of research to emerge recently examines
the efﬁcacy of rTMS on addiction and RD by targeting craving in
particular.
Experimental studies suggest that there is indeed a dopaminer-
gic dysfunction of the mesolimbic systems in addicts (Goodman,
2008). According to some authors, symptoms of addiction and
RD could be alleviated by “boosting” dopaminergic transmission
(Diana, 2011), which may  be achieved via TMS.
Because of their deep brain localisation, dopaminergic neurons
are indirectly stimulated during rTMS, through their more superﬁ-
cial projections, especially in the DLPFC (Diana, 2011). The DLPFC is
involved in cognitive control and the physiopathology of impulse
control disorders, such as addiction and RD (Crockford et al., 2005;
Wang et al., 2007; Van Holst et al., 2010). rTMS applied to the
DLPFC may  therefore indirectly modulate dopaminergic pathways
(Addolorato et al., 2012) and may  consequently have an impact
on the symptoms of addiction (Keck et al., 2002; Feil and Zangen,
2010): cognitive control could be improved and/or cravings could
be reduced (Jansen et al., 2013).
The ﬁrst articles to assess the value of rTMS to treat addictive
disorders date back to 2003 (Eichhammer et al., 2003; Johann et al.,
2003). Uncovering a role for rTMS treatment for addiction and RD
has been approached from a number of different perspectives and
in many different ways (original research, reviews, and comprehen-
sive work), namely by focusing on case studies (Hausmann et al.,
2004; De Ridder et al., 2011; Downar et al., 2012; McClelland et al.,
2013b; Baczynski et al., 2014); one substance at a time (Hoppner
et al., 2011; Nardone et al., 2012; Wing et al., 2013); including all
SUDs (Barr et al., 2008; Feil and Zangen, 2010; Barr et al., 2011;
Addolorato et al., 2012; Bellamoli et al., 2014); eating disorders
(Van den Eynde and Guillaume, 2012; McClelland et al., 2013a);
one symptom of addiction at a time, such as craving (Jansen et al.,
2013); dependence, or cognitive impairment (Knoch et al., 2006);
comprehensive physiopathological approaches (Keck et al., 2002;
Strafella et al., 2003; Barr et al., 2008; Camus et al., 2009; Cho and
Strafella, 2009; Diana, 2011; Hayashi et al., 2013); one neuromod-
ulation technique at a time (Barr et al., 2008, 2011; Hoppner et al.,
2011; Addolorato et al., 2012; Bellamoli et al., 2013; Rosenberg
et al., 2013) or several techniques investigated simultaneously (Feil
and Zangen, 2010; Van den Eynde and Guillaume, 2012; Jansen
et al., 2013; Wing et al., 2013). Several “magnetic techniques”
have also been tested in addiction and RD such as transcranial
dynamic magnetotherapy (TcDMT) in the complex treatment of
alcohol withdrawal syndrome (Staroverov et al., 2009) and deep
TMS  in pathological gambling (Rosenberg et al., 2013). Although
these techniques use magnetic ﬁelds, they are not completely com-
parable to rTMS. Their mechanistic properties, working on the
principle of electromagnetic induction are similar. However, they
differ regarding their depth of penetration and the focality of the
magnetic ﬁeld, mainly because they use different coils. rTMS most
often uses a ﬁgure-8 coil, which induces an electric ﬁeld restricted
to superﬁcial cortical targets, up to 3 cm (Rossi et al., 2009) due
to its rapid attenuation in depth. Deep TMS  is designed to reach
greater depths than rTMS, reaching up to 6 cm (Bersani et al., 2013)
via an H-coil. Figure-8 coils produce a more focal and shallower
stimulation compared to H-coils.
First and foremost, we support the idea that all types of
addiction can be compared using a comprehensive approach that
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Number of studies identified 
through searches = 638 
Included studies = 18 
Screening inclusion criteria 
- The target problem was a SUD or 
related disorder 
- The intervention consisted of rTMS 
- The study was a clinical trial 
Screening exclusion criteria 
- Animal models 
- Studies into risk-taking behaviour or decision-making 
- Lack of methodological data 
- Addictions with mood and psychotic comorbidities in particular 
- Studies with only a physiopathological aim 
- Case reports 
- Reviews 
Unduplicated research = 484
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The data extraction work was divided between the two
authors. Extracted data included clinical, general, and technical
considerations.Fig. 1. Flow diagram of the sear
onsiders physiopathological, clinical and therapeutic aspects. In
his paper, we consider both addiction and RD. We  also support
he idea that behavioural changes ought to be considered, not
ust craving. Finally, we think that a systematic comparison of all
on-invasive neuromodulation techniques (e.g., transcranial Direct
urrent Stimulation and rTMS) is not plausible because these tech-
iques do not share the same procedures and because research
n this ﬁeld is too recent and heterogeneous to currently perform
peciﬁc meta-analyses.
The purpose of this article is to critically review the progress
n the use of rTMS since its inception to treat addiction and RD,
nd in particular the developments in its therapeutic efﬁcacy. This
s particularly important as it will allow us to identify the most
uccessful approaches, summarise the progress made, and high-
ight the lessons to be learned from the difﬁculties encountered.
his review will ﬁrst discuss the methodological issues, followed by
he technical issues of rTMS applied to addiction and RD. Finally,
uture directions and key recommendations will be proposed. To
ur knowledge, this work is the ﬁrst to provide a summary that
overs all types of addiction, including SUD and RD in the ﬁeld of
TMS and to offer a critical assessment of the methodological and
echnical issues raised.
. Methods
.1. Search strategy
We  identiﬁed articles for inclusion in this review by search-
ng the MEDLINE and ScienceDirect databases up to December
013, limiting the search to articles published in English and
erman (one article). The key words used were “TMS” or
rTMS” AND one of the following terms: “addiction”, “alco-
ol”, “amphetamine”, “methamphetamine”, “anorexia nervosa”,
behavioural addiction”, “benzodiazepine”, “binge eating dis-
rder”, “bulimia nervosa”, “cannabis”, “cocaine”, “compulsive
uying/shopping”, “craving”, “DLPFC”, “dopamine”, “drug”, “eatingategy and selection procedure.
disorder”, “ecstasy”, “EDNOS”1, “exercise”, “food craving”, “impuls-
ivity”, “LSD”, “nicotine”, “opiate”, “pathological gambling”, “sex
addiction”, “smoking”, “sport addiction”, and “tobacco”. A manual
search and a screening of the bibliography of the selected studies
were performed in addition to the computerised screening. Dupli-
cate searches were eliminated. The search strategy is summarised
in Figure 1.
2.2. Eligibility criteria
Studies had to fulﬁl the following criteria to be included:
- The target problem was an addiction, a RD or craving
- The intervention was performed using rTMS
- The study was  a clinical trial (e.g., any research study concerning
human beings, including pilot studies and randomised clinical
trials) (WHO, 2014).
2.3. Study selection
First, all studies were screened based on their titles and
abstracts. Second, the two  authors read the full text of all studies
identiﬁed in this search process. They carried out this work inde-
pendently using the same bibliographic search. In the event of a
disagreement between them, the relevant studies were discussed.
2.4. Data extraction1 In the rest of the text, we refer to the DSM-IV because the studies we  have
selected have been carried out prior to the DSM-5 publication. “EDNOS” (eating
disorder not otherwise speciﬁed) (DSM-IV) was replaced by “OSFED” (DSM-5).
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. Results
Eighteen articles met  the criteria for inclusion.
The disorders tested were nicotine, alcohol, cocaine and
ethamphetamine dependence, and eating disorders (food crav-
ng, AN, BN and EDNOS). Of the 18 studies included, only one was a
on-controlled study (Politi et al., 2008). To the best of our knowl-
dge, we assume that rTMS has not yet been tested in the following
ddictive disorders: ecstasy, LSD or opiate use disorders, compul-
ive buying/shopping, pathological gambling, sex addiction and
xercise addiction.
.1. Efﬁcacy of rTMS
The results are summarised in Table 1.
.1.1. rTMS and nicotine
The ﬁrst studies to test the efﬁcacy of rTMS in the sphere
f addictions were carried out in nicotine-dependent subjects
Eichhammer et al., 2003; Johann et al., 2003). Both studies adopted
 crossover design. In one of the studies, two sessions were carried
ut, compared to four sessions in the other study. Compared to
he placebo, real stimulation produced a signiﬁcant reduction in
ravings (Johann et al., 2003) and in cigarette consumption dur-
ng the hours that followed rTMS (Eichhammer et al., 2003). Later,
miaz and colleagues used a design with parallel groups of 10 daily
essions followed by a maintenance period (Amiaz et al., 2009).
he authors observed signiﬁcant reductions in cigarette consump-
ion (assessed by urine cotinine levels) and nicotine dependence
assessed by the Fagerström test). Exposure to smoking-related
ues followed by active rTMS produced a speciﬁc positive effect
fter 10 sessions by reducing the craving for nicotine, which tended
o disappear after 6 months. Another trial offered additional infor-
ation to improve our understanding of the inﬂuence of the
uperior frontal gyrus on nicotine craving rather than being a real
est of the efﬁcacy of rTMS (Rose et al., 2011). These studies are
escribed in the literature review by Wing et al. (2013). This review
lso reports preliminary work with the aim of studying the efﬁ-
acy of rTMS combined with nicotine replacement in subjects with
trong nicotine dependence but also suffering from schizophrenia
Wing et al., 2012). This study was not included in our analysis
ecause of this speciﬁc comorbidity. Finally, the last study suc-
essfully demonstrated that a single session of HF rTMS over the
LPFC could signiﬁcantly reduce cigarette craving induced by cue
xposure (Li et al., 2013a).
.1.2. rTMS and alcohol
Despite the strong prevalence of alcohol use disorders and the
bsence of effective treatment for some patients, rTMS has only
een tested on alcohol-dependent patients very recently. We  have
isted three studies that included alcohol-dependent subjects who
ad just completed detoxiﬁcation. Two of the studies used 10 daily
essions of rTMS, applied to the right (Mishra et al., 2010) or left
Hoppner et al., 2011) DLPFC. The third study adopted a crossover
esign with two rTMS sessions, one active and one placebo, applied
o the right DLPFC (Herremans et al., 2012). The study by Mishra and
olleagues was carried out as a single blind trial and indicated that
eal stimulation was superior, with a reduction in craving lasting for
our weeks after the completion of the active rTMS sessions (Mishra
t al., 2010). Conversely, the next two studies reported negative
esults as they failed to show a signiﬁcant reduction in craving after
ctive rTMS (Hoppner et al., 2011; Herremans et al., 2012)..1.3. rTMS and cocaine
As far as we are aware, only two studies have been published
ith the aim of evaluating the efﬁcacy of rTMS on craving among Biobehavioral Reviews 47 (2014) 592–613
cocaine-dependent subjects. All of the patients studied had previ-
ously completed their cocaine detoxiﬁcation. In both studies, the
authors concluded that rTMS had a positive effect. Nevertheless,
there were a number of important differences between these stud-
ies. The aim of the ﬁrst study was  to compare the effects of rTMS
according to the side of the brain it was applied to (Camprodon
et al., 2007). The results showed that rTMS had only a transient
effect. In contrast, the other study was  not controlled but was of
interest because it showed that 10 daily sessions of rTMS delivered
to the left DLPFC produced a signiﬁcant reduction in craving over
time (Politi et al., 2008). Despite these promising results, no further
studies have been reported.
3.1.4. rTMS and methamphetamine
In a single-blind, sham-controlled crossover study, Li and
colleagues recently suggested that LF rTMS on the left DLPFC
transiently increased cue-induced craving in methamphetamine
participants (Li et al., 2013b).
3.1.5. rTMS and food
The body of literature in the ﬁeld of eating disorders, and more
broadly that of food craving, provides the most evidence of rTMS
treatment efﬁcacy. Seven studies have been published to date. Five
of these were carried out by the same team (Uher et al., 2005; Van
den Eynde et al., 2010a, 2010b, 2013; Claudino et al., 2011), which
probably explains their similarities, and two  of them were based
on patients included in a previous study (Van den Eynde et al.,
2010b). All of these studies except one (Van den Eynde et al., 2010b)
included only women  who had a history of BN or EDNOS-bulimic
type (Walpoth et al., 2008; Van den Eynde et al., 2010a, 2010b;
Claudino et al., 2011). For the most part, the studies were ran-
domised, double-blind, sham-controlled, parallel group trials. All
except one (Walpoth et al., 2008) aimed to investigate the efﬁcacy
of a single rTMS session delivered to the left DLPFC on induced
food craving. In most of the studies the assessment criteria were
score variations on Visual Analogue Scales. One study used a more
objective physiological measurement of craving, by repeating sali-
vary cortisol assays (Claudino et al., 2011), while another chose to
use an indirect reﬂection of craving based on the change in fre-
quency of binges and purges (Walpoth et al., 2008). As shown in
summary Table 1, four of the seven studies listed concluded that
rTMS is effective.
3.2. rTMS technical procedures
The results are summarised in Table 2.
3.2.1. The rTMS device
The equipment most frequently used was MagStim (12 studies),
far ahead of Neuronetics (three studies). Only three studies failed
to specify the equipment used. Most of the studies in which the
equipment was speciﬁed used focal coils, such as the 8-ﬁgured coil.
3.2.2. Stimulation site and identiﬁcation of the target site
The cortical target most often selected was the left DLPFC (14
studies) with the right DLPFC being chosen much less frequently
(two studies). Just one study compared the efﬁcacy of both target
regions (Camprodon et al., 2007). Another chose to compare SFG
and MOC  (Rose et al., 2011). The DLPFC was  most often located using
the “5 cm”  or “6 cm”  empirical method (10 studies), by moving the
coil 5 or 6 cm anterior to the motor cortex, along a parasagittal
line (Herbsman et al., 2009; George and Post, 2011). Two studies
used the international EEG system or “10–20 method” (Hoppner
et al., 2011; Rose et al., 2011). Only one study used neuronavigation
with 3D-MRI (Herremans et al., 2012). Only four studies failed to
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Table 1
Clinical trials of rTMS for addiction and related disorders: clinical and general considerations.
Studies N Participants Mean age
(years)
Proportion
of males
Main exclusion
criteria
Design Objective Outcome measures Main results Drop-oup
Nicotine
Johann et al.
(2003)
11 Nicotine
dependence
(FTND), motivation
to quit smoking.
35 (23–55) 18.2% Psychiatric
disorders and SUD.
Randomised,
double-blind,
sham-controlled,
crossover trial
One active and one
sham rTMS sessions on
2 consecutive days.
Investigate the
effect of rTMS on
cigarette craving.
Measure of craving
(VAS)
Positive
Signiﬁcant
reduction in
craving after the
real rTMS for 9
participants.
0
Eichhammer
et al. (2003)
14 Nicotine
dependence
(FTND), motivation
to quit smoking.
35.4
(SD = 8.9)
14.2% Psychiatric
disorders and SUD.
Benzodiazepines
medication.
Randomised,
double-blind,
sham-controlled,
crossover trial.
Two active and two
sham rTMS sessions on
4 consecutive days.
Investigate the
effect of rTMS on
cigarette smoking
and craving.
Measure of craving
(VAS) and smoking.
Positive
Signiﬁcant
reduction in
smoking in the
active group.
NS
Amiaz et al.
(2009)
52 Nicotine
dependence
(DSM-IV), smoking
>20 cigarettes/day,
motivation to quit
smoking.
47.9 43.7% Psychiatric
disorders.
Current psychiatric
medication.
Randomised,
double-blind and
sham-controlled trial
(four subgroups: active
vs sham
rTMS/smoking-related
vs neural picture cues).
10 daily sessions
followed by a 4-week
maintenance phase.
Investigate the
effect of rTMS on
cigarette smoking,
dependence and
craving.
Levels of cotinine
in urine.
Number of
cigarettes smoked.
FTND, sTCQ.
VAS.
Positive
Per protocol
analysis (N = 48).
Signiﬁcant
reduction in
cigarette smoking
and dependence.
18
Rose et al.
(2011)
15 Smoking >20
cigarettes/day,
CO ≥ 10 ppm,
craving increase ≥1
point upon
exposure to cues.
40.7
(SD = 9.56)
53.3% Psychiatric
disorders and SUD.
Current psychiatric
medication.
Randomised,
sham-controlled trial
At the beginning of
each session, subjects
smoked a cigarette.
One hour later, they
underwent rTMS
concurrently during
exposure to (1) neutral
(2) smoking cues (3)
smoking a cigarette.
Test hypotheses
about the causal
role of SFG in
modulating
craving.
Cue reactivity.
Cigarette
evaluation
questionnaire
Does not provide
evidence of the
utility of rTMS.
NS
598
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Table 1 (Continued)
Studies N Participants Mean age
(years)
Proportion
of males
Main exclusion
criteria
Design Objective Outcome measures Main results Drop-oup
Li et al. (2013a) 16 Nicotine
dependence
(smoking ≥10
cigarettes/day),
CO ≥ 10 ppm,
non-treatment
seeking
42.6
(SD = 11.5)
75% Psychiatric
disorders and SUD.
Current
consumption of
other tobacco
products or
pharmaceutical
aids.
Randomised,
double-blind,
sham-controlled,
crossover trial.
One active and one
sham rTMS sessions
(one-week time
interval).
Participants were
instructed not to
smoke for two hours
before the sessions,
and were then exposed
to scenic, neutral and
smoking cues.
Investigate the
effect of rTMS on
craving.
Measure of craving
(QSU-B) just before
and 15 min after
the rTMS.
Number of
cigarettes smoked.
FTND.
Positive
Per protocol
analysis (N = 14)
Signiﬁcant
reduction in
craving in the
active group.
Positive correlation
between the effect
of rTMS and the
severity of the
dependence.
2
Alcohol
Mishra et al.
(2010)
45 Alcohol
dependence,
inpatients,
CIWA-Ar scores
<  = 10, completion
of detoxiﬁcation.
Participants
received zolpidem
and about ¾ of
them received
anti-craving drugs.
39.3
(SD = 8.9)
vs 38.2
(SD = 6.8)
100% Psychiatric
disorders and SUD.
Single blind,
sham-controlled,
parallel group trial
(without
randomisation).
10  daily sessions.
Investigate the
effect of rTMS on
alcohol craving.
Measure of craving
(ACQ-NOW) at
baseline,
immediately and 4
weeks after the last
rTMS session.
Positive
Signiﬁcant
reduction in
craving after the
last rTMS session in
the active group.
1
Hoppner et al.
(2011)
19 Alcohol
dependence
(DSM-IV),
completion of
detoxiﬁcation.
43.1
(SD = 9.5)
vs 48.0
(SD = 10.7)
Only
women
Cognitive
dysfunctions.
Medication used
for detoxiﬁcation.
Randomised,
sham-controlled trial.
Both groups were
compared to a female
age-matched healthy
control group and were
exposed to neutral,
emotional and
alcohol-related
pictures, before the
ﬁrst and after the last
rTMS session.
Ten daily sessions.
Investigate the
effect of rTMS on
alcohol craving and
mood.
Measure of craving
(OCDS).
Measure of
depressive
symptoms (HDRS,
BDI).
Negative
No signiﬁcant
between-group
difference
regarding craving
and mood.
0
Herremans
et al. (2012)
36 Alcohol
dependence,
completion of
detoxiﬁcation.
49
(SD = 9.96)
67.7% Psychotic episode
and cognitive
dysfunction.
Current
anti-craving
medication.
Randomised, single
blind, sham-controlled
crossover trial.
One active and one
sham rTMS sessions
(one-week time
interval).
Investigate the
effect of rTMS on
alcohol craving.
Measure of craving
(OCDS).
Negative
No signiﬁcant
between-group
difference.
5
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Table 1 (Continued)
Studies N Participants Mean age
(years)
Proportion
of males
Main exclusion
criteria
Design Objective Outcome measures Main results Drop-oup
Cocaine
Camprodon
et al. (2007)
6 Cocaine
dependence
(DSM-IV), inpatient
completion of
detoxiﬁcation.
19–23 100% Current
dependence on
other substance
and psychiatric
disorders.
Psychiatric
medication.
Randomised, crossover
trial (one-week time
interval).
Two rTMS sessions
over left and right
DLPFC.
Investigate the
effect of rTMS on
cocaine craving.
Measure of craving
(VAS).
Measure of anxiety,
happiness, sadness
and discomfort
(VAS).
Positive
Signiﬁcant, but
transient,
reduction of the
craving with the
“right” rTMS (but
no effect with the
“left” rTMS).
0
Politi et al.
(2008)
36 Cocaine
dependence
(DSM-IV),
completion of
detoxiﬁcation.
NS 86.1% NS No controlled study.
Ten daily sessions.
Investigate the
effect of rTMS on
cocaine craving.
Gambling task
SCID II
WAIS-R
Positive
Signiﬁcant over
time reduction of
the craving.
0
Methamphetamine
Li et al. (2013b) 17 MA dependence
(DSM-IV-TR)
10 MA-dependent
users non-seeking
treatment and 8
healthy controls
34.7
(SD = 10.6)
vs 32.5
(SD = 12.6)
50% Psychiatric
disorders.
Psychiatric
medication.
Randomised,
single-blind,
sham-controlled
crossover trial and
healthy controlled trial
(one-hour time
interval).
One active and one
sham rTMS sessions
(one-hour time
interval).
Investigate the
effect of rTMS on
methamphetamine
craving.
Measure of craving
(VAS).
Signiﬁcant, but
transient, increase
of the craving.
0
Food
Uher et al.
(2005)
30 Women  with
normal average
BMI, with strong
urges.
25.2
(SD = 5.4)
vs 26.4
(SD = 4.9)
Only
women
ED, current
psychiatric
disorders and
smoking > 5
cigarettes/day.
Psychiatric
medication.
Randomised, double
blind, sham-controlled,
parallel group trial.
One active or sham
rTMS session.
Investigate the
effect of rTMS on
food craving.
Measure of craving
(VAS), immediately
after food exposure
(before and after
rTMS).
Positive
Prevention of an
increase of food
craving in the real
rTMS group.
2
Walpoth et al.
(2008)
14 BN (DSM-IV). 27.4
(SD = 4.8)
vs 22.6
(SD = 2.6)
Only
women
Severe depressive
symptoms,
BMI  < 17.5.
Psychotherapy and
psychiatric
medication for the
past 3 months.
Randomised, double
blind, sham-controlled,
parallel group trial.
One week of placebo
wash-out, then 15
daily active or sham
rTMS sessions.
Investigate the
effect of rTMS on
binges and purges.
Reduction of at
least 50% in the
frequency of binges
and purges.
Negative
No signiﬁcant
between-group
difference.
0
Van den Eynde
et al. (2010b)
37 BN or
EDNOS-bulimic
type (DSM-IV),
seeking treatment.
30.5
(SD = 11.2)
vs 29.5
(SD = 8.4)
13.1% Smoking >10
cigarettes/day and
substance
dependence.
Psychotropic
medication that
has not been stable
for at least 14 days.
Randomised, double
blind, sham-controlled,
parallel group trial.
One active or sham
rTMS session.
Investigate the
effect of rTMS on
induced food
craving.
Measure of craving
(VAS: “urge to eat”)
before and after
the rTMS.
Positive
Signiﬁcant
reduction in
craving and in the
number of
binge-eating
episodes over the
24-hour follow-up
in the real rTMS
group.
5
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Table 1 (Continued)
Studies N Participants Mean age
(years)
Proportion
of males
Main exclusion
criteria
Design Objective Outcome measures Main results Drop-oup
Van den Eynde
et al. (2010a)
7 Left-handed.
BN or
EDNOS-bulimic
type (DSM-IV),
seeking treatment.
22.9
(SD = 2.9)
vs 28.5
(SD = 9.8)
Only
women
Smoking >15
cigarettes/day and
substance
dependence.
Psychotropic
medication that
has not been stable
for at least 14 days.
Simple blind,
controlled trial.
One active rTMS
session.
The seven left-handed
women were
compared to 14
right-handed women
included in a previous
study (Van den Eynde
et al., 2010b).
All participants
received real rTMS, but
were informed that
they would be
randomised to active
or sham rTMS.
Investigate the
effect of rTMS on
induced food
craving.
Measure of craving
using VAS (“urge to
eat”) before and
after the rTMS.
Negative
No signiﬁcant
within-group and
between-group
difference.
0
Claudino et al.
(2011)
22 BN or
EDNOS-bulimic
type (DSM-IV),
seeking treatment.
28.2
(SD = 9.2)
vs 28.9
(SD = 8.5)
Only
women
Smoking >15
cigarettes/day and
substance
dependence.
Psychotropic
medication that
has not been stable
for at least 14 days.
Randomised, double
blind, sham-controlled,
parallel group study.
One active or sham
rTMS session.
Participants were a
subsample of a larger
research group (Van
den Eynde et al.,
2010b).
Investigate the
effect of rTMS on
induced food
craving.
Salivary cortisol
concentrations at
baseline, pre-rTMS,
post-rTMS, and the
end of the study.
Positive
Signiﬁcant lower
salivary cortisol
concentration in
the real rTMS
group.
3
Barth et al.
(2011)
11 Healthy women
who  endorsed
frequent food
cravings.
28.3
(SD = 6.5)
Only
women
Suicidality.
Medication that
lowers seizure
threshold.
Randomised, double
blind, sham-controlled,
crossover study.
One active and one
sham rTMS sessions
(one-week time
interval).
Food craving was
induced by the
presentation of visual
food cues (IAPS).
Investigate the
effect of rTMS on
induced food
craving.
Measure of craving
(VAS), before and
after rTMS.
Negative
No signiﬁcant
between-group
difference.
Strong placebo
effect.
1
Van den Eynde
et al. (2013)
10 AN (DSM-IV-TR),
seeking treatment
Median
age: 25
(18–44)
Only
women
Smoking >15
cigarettes/day and
substance
dependence.
Psychotropic
medication that
has not been stable
for at least 14 days.
Simple blind trial.
All participants
received one active
rTMS session (but were
informed that they
would be randomised
to sham or active
rTMS).
Investigate the
effect of rTMS on
eating disorder
related symptoms.
Measure of
craving/feelings
(VAS), at baseline,
pre-rTMS,
post-rTMS, at the
end of the study.
Positive
(N = 9)
Signiﬁcant
reduction in the
“feeling fat”,
“feeling full” and
“anxiety” measures
in the real rTMS
group.
1
ACQ-NOW: Alcohol Craving Questionnaire; AN: Anorexia Nervosa; BDI: Beck Depression Inventory; BMI: Body Mass Index; BN: bulimia nervosa; CIWA-Ar: Clinical Institute of Withdrawal Assessment in Alcohol Withdrawal;
CO:  carbon monoxide DLPFC: dorsolateral prefrontal cortex; ED: Eating Disorder; EDE-Q: Eating Disorder Examination-Questionnaire; EDNOS: eating disorder not otherwise speciﬁed; FCQ-S: Food Craving Questionnaire-State;
FTND:  Fagerström Test for Nicotine Dependence; HDRS: Hamilton Depression Rating Scale; HF: high-frequency; IAPS: International Affective Picture System; MA:  Methamphetamine; NS: Non speciﬁed; PAR: parietal cortex;
OCDS:  Obsessive–compulsive Drinking Scale; QSU-B: Questionnaire of Smoking Urges-Brief; rTMS: repeated Transcranial Magnetic Stimulation; sTCQ: short version of the Tobacco Craving Questionnaire; SFG: Superior Frontal
Gyrus;  SUD: Substance Use Disorder; VAS: Visual Analogue Scale; vs: versus; YBOCS: Yale-Brown Obsessive Compulsive Scale.
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Table 2
Clinical trials of rTMS for addiction and related disorders: technical considerations.
Studies Handedness rTMS
device
Stimulation
site (brain
region)
Method for
locating
cortical
target
F (Hz) Method for
determin-
ing
RMT
% of RMT  Number of
trains
ITI (s) Total
pulses per
session
Session
duration
Sham-TMS
procedures
(devices and
methods)
Tolerance/adverse
effects
Nicotine
Johann et al.
(2003)
NS Magstim
active coil
and
sham-coil
system
Left DLPFC NS 20 (HF) NS 90% 20 trains
(2.5 s each)
NS 1000 NS Sham-coil
system
NS
Eichhammer
et al. (2003)
RH Magstim
active coil
and
sham-coil
system
Left DLPFC 5 cm
method
20 (HF) NS 90% 20 trains
(2.5 s each)
42,5 1000 14 min  Sham
stimulation at
the same
location and
frequency,
using a
sham-coil
system
Mild headaches
in 2 cases after
active
stimulation
Amiaz et al.
(2009)
NS Double
70-mm
(ﬁgure-8)
coil
(Magstim)
Left DLPFC 5 cm
method
10 (HF) S◦ of the
motor
strip-
examining
the right
APBM
100% 20 15 NS NS Mu-metal
plates attached
to the active
coil
NS
Rose et al.
(2011)
NS Neuronetics
Model
2100 CRS
SFG or MOC
(side not
speciﬁed)
International
10–20
system for
EEG
10 (HF)
(SFG)
1 (LF) (SFG)
1  (LF)
(MOC)
S◦ of the
motor
strip-
examining
the right
APBM
90% NS NS Greater
number of
pulses for
the 20 Hz
S◦
2 min 30 s
for each
session
No sham
session
NS
Li et al. (2013a) RH Neuronetics
Model
3600 with
a  solid focal
coil TMS
machine
Left DLPFC 6 cm
method
10 (HF) S◦ of the
motor
strip-
examining
the right
APBM
100% 60 trains
(5 s each)
10 3000 15 min  Sham system
using a sham
rTMS coil
Two scalp
electrodes
were located
just below the
hairline,
connected to a
TENSD.
Participants
wore the scalp
electrodes in
both
conditions.
During real
TMS, there was
no current
ﬂowing
through the
scalp
electrodes.
Some
participants
experienced
mild
discomfort at
the start of
stimulation.
Two
participants
dropped out
because of
scheduling
conﬂicts.
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Table 2 (Continued)
Studies Handedness rTMS
device
Stimulation
site (brain
region)
Method for
locating
cortical
target
F (Hz) Method for
determin-
ing
RMT
% of RMT  Number of
trains
ITI (s) Total
pulses per
session
Session
duration
Sham-TMS
procedures
(devices and
methods)
Tolerance/adverse
effects
Alcohol
Mishra et al.
(2010)
RH Magstim
rapid
device
active and
sham
ﬁgure-8
coils
Right
DLPFC
5 cm
method
10 (HF) MEP  110% 20 trains
(4.9 s each)
30 1000 NS Sham ﬁgure-8
coils
Seizure for
patient with
sham (but
recently
stopped
lorazepam),
one scalp pain,
ﬁve transient
headaches,
pain during
delivery of the
stimulation
train, anxiety
for four
patients at ﬁrst
session
Hoppner et al.
(2011)
NS NS Left DLPFC
for the
active coil
F3 (Inter-
national
10–20
system for
EEG)
20 (HF) NS 90% 20 trains
(2.5 s each)
42,5 1000 NS No sham coil
but sham
stimulation
with active coil
applied above
the left
temporal
muscle, angled
at 45◦ , 5 cm
lateral to F3, S◦
intensity
reduced to 60%
RMT
Good/None
Herremans
et al. (2012)
NS Double
70-mm
(ﬁgure-8)
coil
(Magstim)
Right
DLPFC
3D-MRI 20 (HF) Single
pulse TMS
with MEP
110% 40 trains
(1.9 s each)
12 1560 NS Active coil held
angled at 90◦
Single blind
Subjects wore
earplugs and
were
blindfolded
Good/None
Cocaine
Camprodon
et al. (2007)
RH NS Left DLPFC
or right
DLPFC
NS 10 (HF) NS 90% 20 trains
(10 s each)
60 NS NS No sham
session
Good/None
Politi et al.
(2008)
NS Active coil Left DLPFC NS 15 (HF) NS 100% 20 trains
(2 s each)
30 NS NS No sham
session
NS
Methamphetamine
Li et al. (2013b) NS Double
70-mm
(ﬁgure-8)
coil
(Magstim)
Left DLPFC 6 cm
method
1 (LF) S◦ of the
motor
strip-
examining
the right
APBM
100% NS NS 900 15 min Active coil held
angled at 45◦
Single blind
Electrical
stimulation
through the
skin on the
subjects’
forehead
Transient mild
scalp
discomfort at
the start of
stimulation in
some
participants
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Table 2 (Continued)
Studies Handedness rTMS
device
Stimulation
site (brain
region)
Method for
locating
cortical
target
F (Hz) Method for
determin-
ing
RMT
% of RMT  Number of
trains
ITI (s) Total
pulses per
session
Session
duration
Sham-TMS
procedures
(devices and
methods)
Tolerance/adverse
effects
Food
Uher et al.
(2005)
RH Magstim
rapid
device real
and sham
ﬁgure-8
coils
Left DLPFC 5 cm
method
10 (HF) S◦ of the
motor
strip-
examining
the right
APBM
110% 20 trains
(5 s each)
55 1000 20 min  Same location
and frequency
using the
sham-coil
system
Physical
discomfort for
one patient
(real session)
Walpoth et al.
(2008)
NS Magstim
rapid
device real
and sham
ﬁgure-8
coils
Left DLPFC NS 20 (HF) NS 120% 10 trains
(10 s each)
60 2000 NS Sham coil
system
No seizure-like
phenomena
were observed
Van den Eynde
et al. (2010b)
RH Magstim
rapid
device real
and sham
ﬁgure-8
coils
Left DLPFC 5 cm
method
10 (HF) S◦ of the
motor
strip-
examining
the right
APBM
110% 20 trains
(5 s each)
55 1000 20 min  Same location
and frequency
using the
sham-coil
system
Blinding
success is
reported (more
successful in
sham-group
than in the real
rTMS group)
- Physical
discomfort for
one patient
(real session)
- Transient
slight headache
for ﬁve patients
in each group
Van den Eynde
et al. (2010a)
LH vs RH Magstim
rapid
device and
ﬁgure-8
coils
Left DLPFC 5 cm
method
10 (HF) S◦ of the
motor
strip-
examining
the right
APBM
110% 20 trains
(5 s each)
55 1000 20 min  NS NS
Claudino et al.
(2011)
RH Magstim
rapid
device real
and sham
ﬁgure-8
coils
Left DLPFC 5 cm
method
10 (HF) S◦ of the
motor
strip-
examining
the right
APBM
110% 20 trains
(5 s each)
55 1000 20 min  Same location
and frequency
using the
sham-coil
system
Blinding
success is
reported (both
successful in
both
sham-group
and real rTMS
group)
NS
604
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Table 2 (Continued)
Studies Handedness rTMS
device
Stimulation
site (brain
region)
Method for
locating
cortical
target
F (Hz) Method for
determin-
ing
RMT
% of RMT  Number of
trains
ITI (s) Total
pulses per
session
Session
duration
Sham-TMS
procedures
(devices and
methods)
Tolerance/adverse
effects
Barth et al.
(2011)
NS Solid focal
coil
Neuronetics®
Left PFC 5 cm
method
10 (HF) S◦ of the
motor
strip-
examining
the right
APBM
100% NS (10 s
each)
20 3000 15 min Scalp
electrodes
connected to
Epix VT®
TENSD
Sham rTMS coil
Blinding
success
reported
(successful,
only 40% of
participants
guessed
correctly)
NS
Van den Eynde
et al. (2013)
RH Magstim
rapid
device real
ﬁgure-8
coil
Left DLPFC 5 cm
method
10 (HF) S◦ of the
motor
strip-
examining
the right
APBM
110% 20 trains
(5 s each)
55 1000 20 min  NB: patients
were informed
they would be
randomised to
either to sham
or real TMS. At
least, all
received real
TMS
Blinding
success
reported (not
successful: all
participants
correctly
guessed their
allocation to
real rTMS)
- Physical
discomfort for
one patient
- Description of
“slight buzzing
in the head”
APBM: Abductor Pollicis Brevis Muscle; DLPFC: DorsoLateral Prefrontal Cortex; EEG: Electro Encephalography Electrode; F: Frequency; HF: High Frequency; ITI: Intertrain Interval; LF: Low Frequency; LH: Left-handed; MC:  Motor
Cortex;  MEP: Motor Evoked Potentials; MOC: Motor Cortex; NS: Non Speciﬁed; PFC: Prefrontal Cortex; RH: Right-handed; RMT: Resting Motor Treshold; rTMS = repetitive Transcranial Magnetic Stimulation; S◦: Stimulation; SFG:
Superior  Frontal Gyrus; TENSD: Transcutaneous Electrical Nerve Stimulation Device; vs: versus; 3D-MRI: 3D Magnetic Resonance Imaging.
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Table  3
Main sources of bias in the studies of rTMS in addiction and related disorders.
Selection bias
Method of recruiting subjects (in particular, with or without treatment participants).
Duration and severity of the addiction or related disorder.
Stage of treatment prior to rTMS (detoxiﬁcation or continuation of substance use).
Observation bias
The Hawthorne effect.
Over or underestimating the intensity of craving.
Placebo effect of rTMS itself.
Placebo effect of therapeutic trials carried out in the ﬁeld of addiction and related disorders.
Order of the placebo session and active session in a crossover study.
Poor targeting of the cerebral area.
Insufﬁcient number of pulses and number of sessions.
Attrition bias (drop out).
Running statistical analyses per protocol.
Confounding bias
Sociodemographic characteristics: age, gender, ethnicity.
Hormonal status.
Volume of grey matter.
Psychiatric and somatic comorbidities.
Handedness.
Psychotropic treatments (in particular, continuation of anti-craving drugs during the trial).
Duration of the session, which may  overlap with the duration required for the craving to subside naturally.
Cumulative and persistent effects of rTMS when the interval between two sessions is very short.
Sample size.
Ability of the treatment-seeking participants to use relapse prevention techniques during cue-induced craving procedure.
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tate that identiﬁcation method that was used (Johann et al., 2003;
amprodon et al., 2007; Politi et al., 2008; Walpoth et al., 2008).
.2.3. General design of the sessions and rTMS parameters
The number of sessions also varied from one study to the next.
ost of them (12) studied the effect of rTMS in a single active
ession compared with a placebo. One third of the studies exam-
ned the effect of rTMS over several sessions, often around a dozen
essions. HF was used in most cases, with 10 Hz being the most
ommon (10 studies). Only two studies tested LF (Rose et al., 2011;
i et al., 2013b). The motor threshold (MT), which in turn deter-
ines the intensity of the rTMS was, in most cases (10 of 18),
etermined using the visual method (i.e., by watching mobilisation
f the long thumb abductor), a less accurate method than using an
lectromyogram (EMG), which was used in two studies (Mishra
t al., 2010; Herremans et al., 2012). Six studies did not list details
or this parameter. The intensity used, as a percentage of resting MT,
anged from 90% (5 studies) to 120% (1 study). The majority of stud-
es used intensities between 100% (5 studies) and 110% (7 studies).
 considerable majority of the studies (12) divided stimulation into
0 trains. The inter-train interval, which is also a safety parameter,
as greater than 20 s (a maximum of 60 s) in 12 studies. The total
umber of pulsations, which is an essential parameter for rTMS efﬁ-
acy (Gershon et al., 2003), was most often set at 1000 or above per
ession (13 studies). The duration of the session (15–20 min) was
tipulated in half of the studies.
.2.4. Sham procedures
The placebo method is most often described and in most cases
s based on the use of a sham coil (7 studies). Four studies used
ranscutaneous Electrical Nerve Stimulation (TENS) as well, which
ncreases the effectiveness of the placebo (Walpoth et al., 2008;
arth et al., 2011; Li et al., 2013a, 2013b). Four studies used an
ctive coil, reducing its activity either by inclination at an angle of
5◦–90◦, or by applying a metallic plate to the surface to limit the
pread of the magnetic signal. Only four studies noted the efﬁcacyof blinding (Van den Eynde et al., 2010b, 2013; Barth et al., 2011;
Claudino et al., 2011).
3.2.5. Safety and tolerance
Finally, eight studies did not specify rTMS tolerance, which was
generally good, as shown in four studies in which no side effects
were reported. Only one study reported a case of serious side effects
(seizure, probably due to discontinuing benzodiazepine too soon)
(Mishra et al., 2010).
4. Discussion
Most studies supported rTMS efﬁcacy, especially in the short
term, regardless of the comparison with a sham stimulation. A very
recent meta-analysis argued that non-invasive neurostimulation
of the DLPFC decreases craving levels in substance dependence
(Jansen et al., 2013). However, its efﬁcacy deserves to be dis-
cussed in light of many methodological and technical disparities.
All sources of bias, shown in Table 3, will be discussed.
4.1. Methodological issues
4.1.1. Sample size and scope of application
The scope of application of rTMS is vast and all of the studies
were limited by small sample sizes. The study completed by Amiaz
and colleagues had the highest number of subjects (N = 52), but the
sample was  divided into four groups (Amiaz et al., 2009). To com-
pensate for this disadvantage, many studies were carried out with
a crossover design to generate greater power. Some articles do not
state the duration or severity of the disorder (Camprodon et al.,
2007; Politi et al., 2008; Herremans et al., 2012), whereas these
same variables could not be taken into consideration statistically
in the other studies due to their small sample sizes. In particu-
lar, a study of the link between the measurement of craving and
these dimensional variables, or subgroup analyses (i.e., rTMS efﬁ-
cacy in “short” versus “long duration of the illness” subgroups),
was not performed. Only the study by Li et al. (2013a) found a
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ositive correlation between reduced craving and the severity of
icotine dependence. Age, gender, the neurotoxic effects of psy-
hoactive substances (in particular alcohol) and the neurocognitive
ffect of being underweight are all factors that can inﬂuence the
everity of the disorder. Some patients had completed detoxi-
cation prior to start of the studies (for example: Eichhammer
t al., 2003), when others had been exposed to cues with the
peciﬁc aim of increasing their craving (for example: Uher et al.,
005).
.1.2. Characteristics of the participants
The populations studied were heterogeneous, and this hetero-
eneity may  explain the differences in results. Some participants
ad a characterised disorder (for example: Mishra et al., 2010),
hile others only had a symptom (food craving in healthy peo-
le, for example: Uher et al., 2005). Some of them were previously
etoxiﬁed (for example: Herremans et al., 2012), while others con-
inued to use a substance (for example: Amiaz et al., 2009). Some
f them were undergoing treatment (for example: Hoppner et al.,
011), while others were recruited through advertisements (for
xample: Eichhammer et al., 2003). In this particular case, the par-
icipants wished to quit smoking, but their demand for care was
ot entirely spontaneous. They were only enrolled in an exper-
mental protocol using rTMS, and not in a traditional smoking
essation programme. The main selection bias was primarily linked
o the way the subjects were recruited. Indeed, noting the treat-
ent status of the participants is a crucial issue, and some authors
rgued that non-treatment seeking addicted participants showed
ore cue-induced craving than those who were seeking treatment,
esulting in an overestimation of intensity (Wertz and Sayette,
001; Wilson et al., 2004). When the participants were seeking
r undergoing treatment, it may  be assumed that their disorders
ere more severe and long-standing, alleviating the effect of rTMS.
n the other hand, it may  be argued that participants undergoing
reatment had learned to self-control their cravings. This was all
he more true when they had received prior psychotherapy. In this
ontext, participants could use relapse prevention techniques, such
s thought-stoppage or urge surﬁng, leading to an underestimation
f craving intensity (Wanigaratne et al., 1990). This may  interfere
ith the interpretation of the results, concluding that rTMS is effec-
ive. To our knowledge, participants were not asked to avoid using
elapse prevention techniques during cue-induced craving tasks.
.1.2.1. Age. Elderly subjects and a smaller volume of frontal grey
atter are associated with a poorer response to rTMS (Jorge et al.,
008) for patients with vascular depression. Although patients
ncluded in the studies we reviewed were rather young (under 60
ears old), some of their addictive disorders are known to reduce
rey matter and cortical thickness (Gallinat et al., 2006; Nakama
t al., 2011; Frank et al., 2013; Grodin et al., 2013; Ide et al., 2014).
his consequence may  falsely diminish rTMS efﬁcacy. Indeed, the
TMS magnetic ﬁeld may  not be powerful enough to reach the
ortical layer.
.1.2.2. Gender. Apart from speciﬁc aspects of addiction and RD in
omen, which is not the topic of this review, gender differences
ave yet to be widely studied in the ﬁeld of rTMS and addiction.
ome gender differences have been shown in depressed rats (Yang
t al., 2007) and in schizophrenic humans, with a better response
o rTMS in females (Huber et al., 2003). Moreover, hormonal status
ffects the response of treatment-resistant depression to rTMS in
omen (Huang et al., 2008). It may  also have an inﬂuence on the
linical expression of some addictive conditions, such as bulimic
isorders (Lester et al., 2003), and may  therefore introduce a con-
ounding bias for discussion (Claudino et al., 2011). Biobehavioral Reviews 47 (2014) 592–613
4.1.3. Main exclusion criteria
Psychiatric and somatic comorbidities may  be confounding fac-
tors in assessing rTMS efﬁcacy in addictive conditions. Fortunately,
medical conditions are often an exclusion criterion, because they
can be absolute or relative contraindications for rTMS (Rossi et al.,
2009). Psychiatric conditions may  also interfere. For example, in
eating disorders, improving depressive and obsessive–compulsive
symptoms as well as bingeing and purging symptoms may  high-
light a common physiopathological process rather than the speciﬁc
efﬁcacy of rTMS (Walpoth et al., 2008).
4.1.3.1. Associated treatments. While some of the studies exam-
ined in our review were careful to exclude patients receiving
psychotropic treatments, others included such patients on the con-
dition that treatment had been stable for at least two weeks and
even stipulated that ¾ of the patients received anti-craving drugs
(such as naltrexone, acamprosate, disulﬁram, carbamazepine, or
ﬂuoxetine) after completion of the rTMS sessions (Mishra et al.,
2010). Prescribing this type of treatment may  interfere with the
assessment of craving even when the rTMS is carried out some time
later.
4.1.3.2. Handedness. Just one study highlighted the importance of
this parameter in their results (Van den Eynde et al., 2010a). Half
of the studies do not specify the subjects’ handedness, while the
other half looked at right-handed subjects only. This choice is sel-
dom justiﬁed. Some authors (Mishra et al., 2010) argued that the
application of HF rTMS to the right DLPFC has been hypothesised to
produce trans-synaptic suppression of the left DLPFC (i.e., the dom-
inant hemisphere in right-handed individuals) (Fox et al., 1997).
However, others found that applying HF rTMS to the left DLPFC
in right-handed individuals also reduced craving (Uher et al., 2005;
Van den Eynde et al., 2010b; Li et al., 2013a). These ﬁndings suggest
that handedness may  not be as important a criterion as has been
suggested. Moreover, in some cases the dominant hemisphere may
be the right one in right-handed individuals. According to some
authors, approximately 95–99% of right-handed individuals have
left-hemispheric language dominance, as is the case with approxi-
mately 70% of left-handed individuals (Corballis, 2014). In contrast,
some authors have suggested that left-handed people are more
likely to suffer from mental disorders from childhood (van der
Hoorn et al., 2010) and addictive disorders later in life (Sperling
et al., 2000). When applied to the left DLPFC, rTMS produces dif-
ferent effects in right-handed and left-handed subjects (Van den
Eynde et al., 2010a). Including left-handed individuals in further
studies involves taking these last two facts, clinical and ethical
issues, into account. Indeed, left-handed people should be included
in this research, especially because they may  be more likely to suffer
from mental disorders (van der Hoorn et al., 2010).
4.1.4. Cortical excitability
rTMS aims to modulate cortical excitability. Its effectiveness
greatly depends on the state of neuronal activation in the targeted
brain region at the time of stimulation (Silvanto and Pascual-Leone,
2008). Cortical excitability is determined by a number of factors
(Feil and Zangen, 2010), which, alone or in combination, help
change the level of neuronal activity, thereby changing the resulting
effects of rTMS. It is precisely for this reason that age, gender, men-
strual cycle, level of anxiety or mood, sleep deprivation, substance
abuse, thickness of skull layers or brain atrophy, and psychotropic
treatments must be accounted for before the start of a study (Rossi
et al., 2009). Moreover, ethnicity should be taken into consideration
(Yi et al., 2014).
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.1.5. Design
Most of the studies carried out to date assessed the efﬁcacy of
TMS in reducing craving as assessed by Visual Analogue Scales (for
ore detail, see Table 1). While this tool provides a fast measure-
ent of craving that can easily be repeated, the measurement is
ubjective and ﬂuctuates over time, as well as being subject to the
nﬂuence of other variables. Less often, the main objective was to
nvestigate the effect of rTMS on substance use or eating behaviour.
n these cases, the outcome measures were the number of cigarettes
moked or the number of binges and purges. From a therapeutic
oint of view, the latter type of studies is more relevant, while the
rst type may  be useful as an exploratory study.
The procedures for inducing craving also varied, sometimes
eing controlled by exposure to neutral cues, especially in stud-
es relating to nicotine dependence. Participants may  have been
xposed to cues before and after the rTMS session or during stim-
lation.
Moreover, attrition bias has also been observed in trials includ-
ng several rTMS sessions. One of the most ambitious studies had
 design closest to the protocol used to test rTMS efﬁcacy in major
epression and included measurement of the long-term effect
Amiaz et al., 2009). It also had the largest number of subjects. How-
ver, its results were limited by a high drop-out rate and notably by
he authors’ decision to run statistical analyses per protocol, which
an lead to false positive results.
.2. Technical issues
.2.1. General considerations
First, rTMS protocols vary immensely. Sometimes the protocol
as not speciﬁed or the description was rather vague, whereas
he parameters used can have a direct impact on rTMS efﬁcacy
nd the results of the study. This may  partly explain the occa-
ionally contradictory results that emerge from these studies. It
s therefore difﬁcult to compare the protocols from different tri-
ls, which authors often fail to justify or discuss, especially in older
tudies. Second, the more recent the study was, the more accurate
he description of the protocol. This means that broad comparisons
ave to be drawn. Similarly, the same team tends to use the same
rotocol, which makes more accurate comparison of the results
ossible.
.2.2. The rTMS device
The equipment used may  inﬂuence the results depending on its
ase of handling and intrinsic characteristics. The coil design is also
igniﬁcant and may  interfere with the efﬁcacy of rTMS. The depth
f penetration and focality on the clinical target are the two  main
echnical features of the coil. Up to now, ﬁgure-8 type coils have
xhibited the best depth–focality trade-off, compared with circular
oils (Deng et al., 2013). Because most of the studies used this very
idespread coil, we think this technical point enhanced the efﬁcacy
f rTMS and is not likely to explain the differences between studies.
nterestingly, researchers also recently tested the efﬁcacy of deep
MS  in behavioural addictions (Rosenberg et al., 2013), which has
ot yet been proven.
.2.3. Stimulation site and identiﬁcation of target site
In almost all cases, the brain area stimulated was the left DLPFC.
timulation of the DLPFC can induce the release of dopamine in the
audate nucleus (Strafella et al., 2001). Thus, repeated stimulation
ay  induce neuroadaptation in the dopaminergic system (Strafella
t al., 2003). Other target regions such as the right DLPFC or DMPFC
re also starting to be tested (Downar and Daskalakis, 2013). The
ight DLPFC was rarely chosen; however, testing this target may  be
arranted as it is involved in decision making (Knoch et al., 2006).
e hypothesise that the left DLPFC was more often tested than the Biobehavioral Reviews 47 (2014) 592–613 607
right DLPFC or others targets because researchers built their ﬁrst
studies on studies of rTMS and depression. The choice of target
region, however, is only of relative signiﬁcance when one consid-
ers that rTMS also produces remote effects (Fox et al., 1997; Mishra
et al., 2010). rTMS not only produces local effects facing the coil
but also on the ipsi- and contralateral (inter-hemispheric) corti-
cal side, either inhibiting (Ferbert et al., 1992; Fox et al., 1997) or
facilitating cortical activity (Fox et al., 1997; Hanajima et al., 2001).
Stimulating a target region may  also modulate the excitability of
another one rather than directly stimulating the latter (Rizzo et al.,
2004). These ﬁndings are also supported by neuroimaging evidence
(Bestmann et al., 2005). Moreover, the remote effects of rTMS on
frontal cortical regions have been noticed in deeper cerebral struc-
tures, especially in the mesostriatal system, increasing the release
of dopamine (Keck et al., 2002), and subcortical regions (Hanlon
et al., 2013). For example, stimulation of the DLPFC potentially
increases dopamine excretion in the ventral striatum (Strafella
et al., 2001). In the same way, SFG is also connected to subcortical
structures such as the amygdala and striatum (Croxson et al., 2005).
Therefore, stimulating the DLPFC or SFG may  ultimately both have
remote effects on dopamine release, depending of course on the fre-
quency of stimulation. Because dopamine is particularly involved in
the physiopathological processes of addictions and RD, any modu-
lation of its neurotransmission activity is probably more important
than the initial target where the stimulation takes place.
Nevertheless, the link with the decision making process must
be kept in mind (Bechara, 2005; Redish et al., 2008). The prefrontal
cortex is involved in many aspects of cognitive processes including
decision-making to achieve goal directed behaviours. Moreover, its
activity depends on motivation to seek treatment (Wilson et al.,
2004) and inter-temporal drug availability (McBride et al., 2006;
Hayashi et al., 2013), both related to the issue of self-control.
The methods for identifying the target site have varying levels
of precision. The most commonly used, the “5-cm method”, has
been criticised because it does not take into account interindivid-
ual skull size and anatomical variations in the prefrontal cortex
(Herbsman et al., 2009; Johnson et al., 2013). Neuronavigation
proved to be a superior target location method for DLPFC com-
pared with the “5-cm method” and the “10–20 method” or the
international EEG system (Rusjan et al., 2010; Bradﬁeld et al., 2012;
Kim et al., 2013). Thus, neuronavigational coil positioning seems to
increase the therapeutic effects of rTMS in several diseases such as
depression (Fitzgerald et al., 2009; Schonfeldt-Lecuona et al., 2010;
Nauczyciel et al., 2011), auditory hallucinations (Klirova et al., 2013)
and pain (Ahdab et al., 2010). However, the research has yet to show
evidence for the greater efﬁcacy of rTMS in addictions or RD using
neuronavigation, compared with other coil-positioning methods.
4.2.4. General design of the sessions and rTMS parameters
4.2.4.1. Number of sessions. The number of rTMS sessions received
by the participants ranged from 1 to 15, and was inﬂuenced by
the aim of the study and the chosen outcome measures. Changes in
behaviour and long-lasting effects were more often seen in patients
undergoing repeated rTMS sessions. Similar evidence is seen in the
treatment of major depression (Lam et al., 2008). If participants
underwent several sessions, the interval between the two sessions
varied from one hour to one week. Little is known about the cumu-
lative and persistent effects of rTMS over time in the treatment of
addictions and RD. These particular effects are usually identiﬁed by
parallel group trials; however, they may  result in misinterpretation
if a crossover design is used, particularly when the interval is short
(Eichhammer et al., 2003; Johann et al., 2003) or even very short (Li
et al., 2013b).
4.2.4.2. Frequency. HF was  used in all of the studies, except two
(Rose et al., 2011; Li et al., 2013b). As previously mentioned, HF
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timulation is considered to have excitatory effects on both left
nd right cortical activity. Regarding the frequency and target
ite, most of the studies we reviewed showed that HF applied
o the left DLPFC had positive results on craving or dependence,
hereas others found negative results on craving. When HF is
pplied to the right DLPFC, two studies showed a positive effect
n craving and only one study found a negative effect. It is unfor-
unate that this decision (HF or LF) was not always motivated
y underlying physiopathological hypotheses. When mentioned,
he main hypothesis is that HF rTMS has been shown to alter
opaminergic neurotransmission in subcortical structures
Eichhammer et al., 2003). Researchers sometimes tend to
eplicate parameters used by previous teams, without explaining
heir own hypothesis. It is only recently that LF protocols have
egun to be tested. Li et al. (2013b) chose LF for two  reasons, the
rst being safety because individuals with a history of MA usually
xhibit signiﬁcantly increased cortical excitability and often show
ncreased seizure susceptibility, and the second was  listed simply
s “exploratory”. They assumed that LF rTMS, which is inhibitory,
ould modulate cravings and perhaps even worsen cravings.
inally, they showed that LF rTMS on the left DLPFC transiently
ncreased cue-induced craving in MA  participants. Hence, reducing
nhibitory control might be one of the possible mechanisms of the
F rTMS. Stimulating the right DLPFC with HF rTMS may  result in
rans-synaptic suppression of the left DLPFC (Camprodon et al.,
007; Mishra et al., 2010). Thus we support the idea that the choice
f HF or LF in any trial should be made in consideration of other
arameters, especially the target site.
.2.4.3. Motor threshold and the intensity of stimulation. Although
 visual determination of MT  should preferably be avoided, as it
ends to overestimate the minimal intensity required to activate
he motor cortex (Lefaucheur et al., 2011), it was widely used in the
tudies. While rather troublesome to use, the EMG  method is more
ccurate and, more importantly, can be accurately reproduced. The
ntensity of stimulation thus determines rTMS efﬁcacy. Even if the
timulation intensity at the motor cortex gives an accurate result,
here is no evidence that this is more optimal than that at the
refrontal cortex for therapeutic purposes. However, using visual
etermination of the MT  could artiﬁcially increase the patient’s real
T,  and lead to a higher intensity rTMS than that predicted by the
rotocol. This could thus result in incorrect interpretations and may
nterfere with the safety of rTMS. Over 100% intensity is thought to
e a predictive rTMS response factor in depression (Gershon et al.,
003). It seems that this is also the case for addiction and RD.
.2.4.4. The number of trains, intertrain interval, numbers of pulses,
nd number and duration of sessions. The number of trains, inter-
rain intervals and pulses per train should be described more often,
n line with safety regulations (Rossi et al., 2009). The total number
f pulses per session was between 1000 and 2000 in most trials,
hich seems to be suitable for ensuring effective rTMS. Two recent
tudies actually used 3000 pulses (Barth et al., 2011; Li et al., 2013a).
n fact, a ﬁgure higher than 1000 is thought to be predictive of rTMS
fﬁcacy in depression (Gershon et al., 2003), while the number of
essions is said to determine the efﬁcacy of rTMS in the medium
nd long term (Gershon et al., 2003; Khedr et al., 2005; Amiaz et al.,
009). In most of the studies examined here, rTMS was  carried
ut in a single session. The effects thus seemed to be very short-
ived, lasting from a few seconds to a few minutes. The duration of
he session, which was not always stipulated, is nevertheless also
 determining factor in regard to assessing the speciﬁc effect of
TMS on craving. The natural progression of craving remains poorly
nderstood. According to some authors, craving may  be sustained
or 30 min  following exposure to cues, with a gradual decrease
n intensity (Heishman et al., 2010). It may  be hypothesised that Biobehavioral Reviews 47 (2014) 592–613
under certain conditions (for example, during an excessively long
session), craving intensity may  actually diminish naturally over the
course of a few minutes, and it may  instead have been incorrectly
attributed to a speciﬁc effect of the rTMS. While this risk does exist,
it has largely been mitigated through the design of studies with
control groups.
4.2.5. Sham procedure
The quality of the placebo method is a crucial issue. The reliabil-
ity of the results is substantially undermined when authors fail to
describe the placebo method used or to optimise it. Using a sham
coil alone does not create optimum placebo conditions (Loo et al.,
2000) because, among other reasons, it does not produce a tac-
tile sensation on the face or scalp. Fortunately, the placebo method
has been gradually improved over time. First, some research teams
used electrical stimulation through the skin on the subjects’ fore-
head, over the prefrontal cortex, triggered by the rTMS machine
to correspond to sham rTMS pulses (Li et al., 2013a). Second, the
electrical current was titrated to a level matching participants’ rat-
ings of real rTMS (Barth et al., 2011; Li et al., 2013a). Third, some
researchers also tested the validity of the sham system at the end of
the study by asking participants to guess which rTMS session was
real and which was sham (Barth et al., 2011).
The Hawthorne effect is probably at work when subjects can
distinguish between the placebo and the active method. Expres-
sions of craving are eminently subjective, and its intensity may
be overestimated or underestimated if the placebo method has
not been optimised (Brunoni et al., 2009). This was the case for
most of the studies, especially where the sham method consisted
of simply applying the active coil to the target area at an angle
of 45◦–90◦. In this situation, there is probably still slight activity,
possibly modulating cortical excitability. There are still too few
studies examining the reliability of the placebo method through
a patient survey (Broadbent et al., 2011). Furthermore, the rTMS
placebo effect may  be linked to the disorder being studied and the
study design rather than the treatment itself (Brunoni et al., 2009).
A strong placebo effect is often reported in therapeutic trials carried
out in the ﬁeld of addiction and RD (Hodgins et al., 2011). Moreover,
it has been shown that in crossover studies, a placebo session prior
to the active session artiﬁcially increases the effect of the latter
(Andre-Obadia et al., 2011).
Although blinding efﬁcacy is seldom reported, it is neverthe-
less a critical component in determining the magnitude of placebo
effects in controlled rTMS studies. Assessing the efﬁcacy of blinding
should be very helpful for further studies.
4.2.6. Safety and tolerance
Apart from conventional safety recommendations and respec-
ting the exclusion criteria for rTMS, speciﬁc points related to
addictions must be noted (Rossi et al., 2009). First, patients exposed
to drugs of abuse often show increased seizure susceptibility, and
second withdrawal from alcohol or benzodiazepines increases the
risk of developing a seizure threshold (Kawasaki et al., 2012; Leach
et al., 2012; Ghezzi et al., 2014). Safety, more than tolerance, which
is often good, needs to be balanced with the parameters, especially
the frequency, number of pulses, intensity, and number of sessions,
required to provide rTMS efﬁcacy.
5. Future directions
Overall, the use of rTMS in patients with addictions and RD does
seem to be a promising treatment that merits further research.
Nevertheless, this critical review leads us to propose key recom-
mendations (Table 4). Neuromodulation may increase cognitive
control in various ways, opening up new treatment prospects to
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Table  4
Key recommendations for further studies on rTMS in addiction and related disorders.
Main issues Key recommendations
Clinical and general considerations
Lack of treatment and intervention in
addictions and related disorders
Testing neuromodulation through rTMS of each addiction and related disorder.
Knowledge of the physiopathology of
addictions and related disorders
Coupling neuroimaging and functional investigations with rTMS to enhance the knowledge of physiopathology and
then argue the choice of parameters.
Design Developing controlled, randomised, double-blind studies, based on larger sample groups.
Replicating trials.
Discussing all sources of bias.
Inducing craving procedures Better understanding of the natural ﬂuctuations of craving.
Justifying the choice of instant of cue-inducing craving in relation with the rTMS session and assessment.
Asking seeking-treatment participants to avoid using relapse prevention techniques during the cue-induced craving
procedure.
Outcome and assessment criteria Coupling subjective assessment and objective and physiological measurements.
Developing other criteria (such as changes in behaviour).
Increasing study follow-up to examine the long-lasting effect of rTMS.
Potential indications for rTMS in
addictions and related disorders
Developing clinical (and eventually biological) predictors of treatment outcome.
Technical considerations
Comprehensive assessment of the
treatment effect and
physiopathological hypothesis
Measuring neurophysiological and neuroimaging variables regularly throughout the rTMS trial.
Lack  of details of rTMS procedures Describing rTMS parameters accurately and justifying them.
Handedness Determining handedness carefully using an appropriate questionnaire.
Including left-handed individuals in the studies.
rTMS  device: type of coil Choosing the appropriate type of coil for the target site (based on its depth of penetration and focality).
Stimulation site Testing regions other than the DLPFC.
Using individualised techniques to locate the target site (international EEG system, neuronavigation) to conduct
reproducible and reliable studies.
rTMS parameters Using a reproducible method to determine the motor threshold, such as the EMG  method.
Increasing the number of sessions, number of pulses and intensity within a safety context.
Choosing HF or LF according to the target site, basing oneself on a physiopathological hypothesis.
Specifying session duration so as to discuss it in the light of craving evolution if craving is the main outcome.
Giving all the rTMS parameters accurately so as to conduct replicating trials and further meta-analyses.
Sham  procedure Using an electrical stimulation.
Reporting and discussing blinding success.
Safety and tolerance Systematically reporting safety and tolerance.
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elp addicted patients by reducing their craving levels (Jansen et al.,
013).
Both the efﬁcacy of this method and real indications for its use
as yet to be conﬁrmed. Research should therefore continue by
eplicating the trials, with particular attention given to their design.
ontrolled, randomised, double-blind studies, based on larger sam-
le groups should be standard practice. Some authors recommend
arrying out international multicentre studies as a way of overcom-
ng recruitment difﬁculties (Van den Eynde and Guillaume, 2012).
In addition, the choice of main assessment criteria is crucial.
ssessing craving using a VAS is extremely subjective and ﬂuc-
uates over time under the inﬂuence of many factors. A better
nderstanding of the natural ﬂuctuations in cravings is key to
educing factors of confusion. Moreover, the measurement of crav-
ng intensity could be coupled with approximate but objective and
hysiological measurements of craving (Claudino et al., 2011). Mea-
urement of indirect criteria might also be added to this, such as
valuations of a change in behaviour (for example, a reduction in
he number of cigarettes smoked or in the number of binges), pro-
ided that the effect of rTMS is evaluated in the medium term, as
as done in some of the described studies (Walpoth et al., 2008;
miaz et al., 2009) and as is recommended by some researchers
Wing et al., 2012).
As previously mentioned, the beneﬁcial effect observed in most
f the studies is only a short-term effect, limiting the interven-
ion’s usefulness. Some authors have conducted studies with the
esign used in the treatment of major depression, with repeated
aily sessions of rTMS over a period of several weeks. This design
hould provide a long-lasting effect. Several authors argue that rTMS parameters.
studies should be developed according to this model based on the
hypothesis that repeated, frequent sessions will result in changes
in cerebral neuroplasticity and generate a long-lasting effect (Van
den Eynde and Guillaume, 2012). Moreover, the use of multiple
rTMS sessions per day may  also be a promising therapeutic devel-
opment, as shown very recently in depression (Baeken et al., 2013).
The efﬁcacy of rTMS should be greatly enhanced when the number
of pulses is high (Gershon et al., 2003). In patients with addictions
and RD, several rTMS sessions per day may  alleviate efﬁcacy by
increasing the number of pulses. We  also hypothesise that it may
reduce craving, a key symptom in addiction, which may  occur sev-
eral times a day. Safety concerns related to giving several rTMS
sessions a day should also be assessed.
Handedness should be considered as one of the inclu-
sion/exclusion criteria and subject handedness should be carefully
researched using an appropriate questionnaire. Including left-
handed individuals may  improve our understanding of brain
functioning (Willems et al., 2014).
Developing better knowledge of brain mapping in patients with
addiction may  help determine which brain regions other than the
DLPFC could be tested. This may  not be as important as it appears
because of the remote effects of rTMS, which have been discussed
above. Finally, the hemispheric differences of the DLPFC in addic-
tion should also be a matter of debate. These unresolved issues
should be clariﬁed in future studies. They are all the more important
because hemispheric differences in human beings are still being
discussed (Corballis, 2014). For this reason, both left- and right-
sided rTMS could be compared in the same trial to clarify the role
of the two  sides in regulating craving. In the future, identiﬁcation
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f the target area may  rely on methods other than the “5-cm”
ethod, as evidenced by the superior efﬁcacy of neuronavigation
n the treatment of depression. This statement must be taken very
arefully because to date, no evidence of the superiority of neuron-
vigation has yet been found for rTMS in patients with addictions
nd RD. LF rTMS on both the right and left DLPFC should be tested
o specify more precisely whether it might inﬂuence craving or not.
nhibition by LF in regions in which hyperactivity is discovered dur-
ng craving induction, especially the right DLPFC (Wang et al., 2007)
ould be interesting. LF is all the more interesting for safety reasons,
ith a lower risk of seizure compared with HF.
The intensity of treatment and the number of pulses per session
ould be increased and still remain in line with safety regula-
ions (Rossi et al., 2009). Optimising and standardising stimulation
arameters does present a challenge but is a necessary step that
any authors have called for (Barr et al., 2008; Feil and Zangen,
010; Diana, 2011; Wing et al., 2012). Detailed descriptions of the
rotocols used in the articles would enhance the repeatability of
hese trials and thus facilitate comparisons of the results of dif-
erent studies. This would be a ﬁrst step towards meta-analyses
hat would be useful for interpreting results as suggested by some
uthors (Van den Eynde and Guillaume, 2012).
Moreover, clinical and non-clinical predictors of treatment out-
omes must be determined to provide more detailed indications of
euromodulation. To our knowledge, only one study reached the
onclusion that rTMS had a more intense effect on heavy smok-
rs than light smokers (Li et al., 2013a) (for a description of the
arameters, see Table 2). In other areas, work on outcome pre-
ictors identiﬁed exogenic and endogenic factors. Variability in
ortical excitability may  also be linked to genetic characteristics,
n the same way that responses to medications can be inﬂu-
nced by genetic variability (Sturgess et al., 2011). In contrast, the
odulation of several genes may  be involved in the therapeutic
echanisms of rTMS (Ikeda et al., 2013).
Finally, physiological measurements, such as electroen-
ephalography, PET-scan or fMRI, should be associated with
linical studies to enhance our knowledge of the underlying
echanisms of both addictions and RD, particularly concerning
he dopaminergic brain reward systems and rTMS action (Pripﬂ
t al., 2013b).
Implementation of these recommendations would allow neu-
omodulation through rTMS to take its place in the spectrum
f therapeutic strategies, alongside other neuromodulation tech-
iques, psychotherapies and pharmacotherapies.
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